177Lu-PSMA-I&T在低体积寡转移激素敏感性前列腺癌中的剂量学分析:LUNAR试验二次分析
LUNAR试验将寡复发激素敏感性前列腺癌患者随机分为新辅助[177Lu]Lu-PSMA-I&T(2周期,6.8 GBq)序贯立体定向体部放疗(SBRT)组与单纯SBRT组。本二次分析对试验组45例患者进行剂量学评估,估算危及器官和病灶的吸收剂量。结果显示危及器官吸收剂量与既往报道一致,支持其安全性,但病灶吸收剂量在患者间和患者内存在显著异质性。
要点
- 肾、腮腺、下颌下腺、泪腺、肝脏和骨髓的吸收剂量分别为0.35±0.10、0.20±0.10、0.24±0.10、0.70±0.49、0.03±0.01和0.005±0.002 Gy/GBq。
- 骨、淋巴结和软组织病灶的平均吸收剂量分别为0.19±0.42、0.46±0.81和0.30±0.38 Gy/GBq。
- 病灶吸收剂量在患者间和患者内存在显著异质性,SPECT空间分辨率有限可导致小体积病灶吸收剂量被低估。
核心结论
- [177Lu]Lu-PSMA-I&T对危及器官的吸收剂量与既往报道一致,支持其在寡复发激素敏感性前列腺癌患者中的安全性。
- 病灶吸收剂量估计在患者间和患者内存在显著异质性。
- 由于SPECT空间分辨率有限,部分容积效应可低估小体积病灶的吸收剂量。
研究设计与样本
- 本分析为2期LUNAR试验的二次分析,纳入随机分配至研究组的全部45例患者。
- 在第1周期注射后4、24和72-96小时采集定量SPECT/CT图像。
- 肾脏、唾液腺和泪腺、肝脏采用深度学习辅助分割,腰椎手动分割作为骨髓替代。
- 吸收剂量采用多时间点体素基方案估算,时间-放射性数据用单指数函数拟合,部分容积效应采用体模基恢复系数校正。
主要发现
- 45例患者中位前列腺特异性抗原为1.10 ng/mL(范围0.16-14.70 ng/mL)。
- 共识别123个病灶,每例患者中位病灶数为2个(范围1-9个)。
- 中位全身总肿瘤体积为14.5 cm3(范围1.9-145.9 cm3)。
- 基线PSMA PET/CT和24小时SPECT/CT的中位SUVmax分别为3.49(范围0.59-45.30)和0.72(范围0.02-34.24)。
关键数值与推荐
- 肾脏、腮腺、下颌下腺、泪腺、肝脏和骨髓的吸收剂量分别为0.35±0.10、0.20±0.10、0.24±0.10、0.70±0.49、0.03±0.01和0.005±0.002 Gy/GBq。
- 骨病灶(n=38)、淋巴结病灶(n=82)和软组织病灶(n=3)的平均吸收剂量分别为0.19±0.42、0.46±0.81和0.30±0.38 Gy/GBq。
临床怎么用
- 该剂量学数据可为[177Lu]Lu-PSMA-I&T在寡复发激素敏感性前列腺癌患者中的安全性评估提供参考。
- 病灶吸收剂量的显著异质性提示需关注患者间和患者内剂量差异对疗效评估的影响。
- SPECT部分容积效应可导致小体积病灶吸收剂量被低估,解读时需加以考虑。
局限性
- SPECT空间分辨率有限,部分容积效应可低估小体积病灶的吸收剂量。
- 腰椎作为骨髓替代进行分割,可能无法完全代表全身骨髓剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phase 2 LUNAR trial randomized (1:1) patients with oligorecurrent hormone-sensitive prostate cancer to neoadjuvant [177Lu]Lu-PSMA-I&T (2 cycles, 6.8 GBq) followed by stereotactic body radiotherapy (SBRT) versus SBRT alone. [177Lu]Lu-PSMA-I&T before SBRT was well tolerated and significantly improved PSMA PET/CT-based progression-free survival compared with SBRT alone. Here, we report the estimated absorbed doses (AD) of [177Lu]Lu-PSMA-I&T to organs at risk and lesions. Methods: This analysis was conducted on all 45 patients randomized to the investigational arm. Quantitative SPECT/CT images were acquired at 4, 24, and 72-96 h postinjection of cycle 1. Kidneys, salivary and lacrimal glands, and liver were delineated with deep learning-assisted segmentation, whereas lumbar vertebrae were manually segmented as a surrogate for bone marrow. Planned target volumes were transferred from the SBRT plans to the SPECT/CT series. Registration between time points was manually verified for each segmentation. ADs were estimated using a multiple-time-point voxel-based schema. Time-activity data were fit using a monoexponential function. Partial-volume effects were corrected using volume-specific phantom-based recovery coefficients. Results: In the 45 patients included, the median prostate-specific antigen was 1.10 ng/mL (range, 0.16-14.70 ng/mL). In total, 123 lesions total were identified, with a median per patient of 2 (range, 1-9). Median whole-body total tumor volume was 14.5 cm3 (range, 1.9-145.9 cm3). Median SUVmax on baseline PSMA PET/CT and 24-h SPECT/CT was 3.49 (range, 0.59-45.30) and 0.72 (range, 0.02-34.24), respectively. The AD to the kidneys, parotids, submandibulars, lacrimals, liver, and bone marrow were 0.35 ± 0.10, 0.20 ± 0.10, 0.24 ± 0.10, 0.70 ± 0.49, 0.03 ± 0.01, and 0.005 ± 0.002 Gy/GBq, respectively. The mean dose to bone (n = 38), lymph node (n = 82), and soft tissue (n = 3) lesions were 0.19 ± 0.42, 0.46 ± 0.81, and 0.30 ± 0.38 Gy/GBq, respectively. Conclusion: The ADs from [177Lu]Lu-PSMA-I&T to organs at risk were consistent with prior reports, supporting the safety in patients with oligorecurrent hormone-sensitive prostate cancer. There was substantial heterogeneity in lesion AD estimates on both inter- and intrapatient levels. Because of the limited spatial resolution of SPECT, partial-volume effects can underestimate the AD in small volumes. Nevertheless, 2 neoadjuvant cycles of [177Lu]Lu-PSMA-I&T before SBRT prolonged progression-free survival, consistent with effective treatment of occult disease beyond imaging detectability.
引用
- Ells Z, Meyer C, Kimura K, et al. Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial. J Nucl Med. 2026. PMID: 41927282. doi:10.2967/jnumed.125.271467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。